Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer—who benefits?

PURPOSE: For years, there have been discussions on whether neoadjuvant radiochemotherapy followed by surgery (nRCT-S) is superior to definitive radiochemotherapy (dRCT) as the standard of care for locoregionally advanced oesophageal cancer (OC). This retrospective study aimed to evaluate our patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiffner, Christoph, Christiansen, Hans, Brandes, Iris, Grannas, Gerrit, Wichmann, Jörn, Merten, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700570/
https://www.ncbi.nlm.nih.gov/pubmed/35416495
http://dx.doi.org/10.1007/s00066-022-01929-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700570/
https://www.ncbi.nlm.nih.gov/pubmed/35416495
http://dx.doi.org/10.1007/s00066-022-01929-y

Ejemplares similares